Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22)
Year of publication
Document Type
- Journal article (22)
Language
- English (22)
Keywords
- HIV (6)
- antiretroviral therapy (3)
- AIDS (2)
- German Hepatitis C-Registry (2)
- chronic hepatitis C (2)
- graft versus host disease (2)
- hepatitis C virus (2)
- infection (2)
- sofosbuvir (2)
- therapeutic drug monitoring (2)
- APRI (1)
- ARDS (acute respiratory distress syndrome) (1)
- BRAF mutation (1)
- COVID-19 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- D insufficiency (1)
- D serum-levels (1)
- FIB-4 (1)
- Germany (1)
- HBV (1)
- HCV cure (1)
- HCV genotype 2 (1)
- HCV genotype-2 (1)
- HCV infection (1)
- HIV diagnosis and management (1)
- HIV infections (1)
- HIV-1-infected patients (1)
- HIV-1-infected subjects (1)
- HIV-infected patients (1)
- IL28B polymorphisms (1)
- LINE-1 retrotransposition (1)
- Mycobacterium avium (1)
- Prednisolon (1)
- Ruxolitinib (1)
- T cells (1)
- Tansania (1)
- Tanzania (1)
- Uganda (1)
- acoustic radiation force impulse imaging (1)
- active antiretroviral therapy (1)
- adults (1)
- afatinib (1)
- all-cause mortality (1)
- antimicrobial resistance (1)
- antiretrovirals (1)
- at-home sampling (1)
- bile (1)
- biomarkers (1)
- chemokines (1)
- chewed (1)
- chronic Hepatitis C (1)
- cirrhosis (1)
- coagulation (1)
- common genetic determinants (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytotoxic T cells (1)
- dabrafenib (1)
- differentiated thyroid tumor (1)
- direct-acting antiviral (1)
- direct-acting antivirals (1)
- disease (1)
- dolutegravir (1)
- drug (1)
- drug adherence (1)
- drug interactions (1)
- drug monitoring (1)
- drug–drug interactions (DDIs) (1)
- elderly persons (1)
- emtricitabine (1)
- epidemology (1)
- fibrin D-dimer (1)
- fibrotest (1)
- glecaprevir/pibrentasvir (1)
- healthy volunteers (1)
- highly-active antiretroviral therapy (1)
- human hepatic cells (1)
- hydroxy-dabrafenib (1)
- i-131 uptake (1)
- immune activation (1)
- immune cells (1)
- indinavir (1)
- integrase inhibitor (1)
- intensive care medicine (1)
- interferon alpha (1)
- interferon-free (1)
- interleukin-6 (1)
- kinase inhibitors (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liver (1)
- liver diseases (1)
- management (1)
- melanoma (1)
- mutation databases (1)
- non-invasive fibrosis assessment (1)
- osimertinib (1)
- overdose (1)
- pandemia (1)
- peginterferon alpha-2B (1)
- peginterferon alpha-2b (1)
- pharmacokinetic (1)
- pharmacokinetic interaction (1)
- pharmacokinetics (1)
- pharmacology (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- plasma D-dimer (1)
- point shear wave elastography (1)
- population pharmacokinetics (1)
- posaconazole (1)
- prostate cancer (1)
- raltegravir (1)
- randomized controlled-trial (1)
- real world evidence (1)
- reverse-transcriptase inhibitors (1)
- routine clinical-practice (1)
- ruxolitinib (1)
- sequence databases (1)
- severe fibrosis (1)
- steatosis (1)
- suicide attempt (1)
- sustained virological response (1)
- tenofovir disaproxil fumarate (1)
- therapy (1)
- toxicity (1)
- trametinib (1)
- transient elastography (1)
- viral clearance (1)
- viral load (1)
- viral replication (1)
- virus infection (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- weight gain (1)
Institute
- Medizinische Klinik und Poliklinik II (17)
- Institut für Virologie und Immunbiologie (5)
- Medizinische Klinik und Poliklinik I (5)
- Institut für Pharmazie und Lebensmittelchemie (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Mathematik (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Missionsärztliche Klinik (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 241447 (1)
Purpose
Knowledge on Ruxolitinib exposure in patients with graft versus host disease (GvHD) is scarce. The purpose of this prospective study was to analyze Ruxolitinib concentrations of GvHD patients and to investigate effects of CYP3A4 and CYP2C9 inhibitors and other covariates as well as concentration-dependent effects.
Methods
262 blood samples of 29 patients with acute or chronic GvHD who were administered Ruxolitinib during clinical routine were analyzed. A population pharmacokinetic model obtained from myelofibrosis patients was adapted to our population and was used to identify relevant pharmacokinetic properties and covariates on drug exposure. Relationships between Ruxolitinib exposure and adverse events were assessed.
Results
Median of individual mean trough serum concentrations was 39.9 ng/mL at 10 mg twice daily (IQR 27.1 ng/mL, range 5.6-99.8 ng/mL). Applying a population pharmacokinetic model revealed that concentrations in our cohort were significantly higher compared to myelofibrosis patients receiving the same daily dose (p < 0.001). Increased Ruxolitinib exposure was caused by a significant reduction in Ruxolitinib clearance by approximately 50%. Additional comedication with at least one strong CYP3A4 or CYP2C9 inhibitor led to a further reduction by 15% (p < 0.05). No other covariate affected pharmacokinetics significantly. Mean trough concentrations of patients requiring dose reduction related to adverse events were significantly elevated (p < 0.05).
Conclusion
Ruxolitinib exposure is increased in GvHD patients in comparison to myelofibrosis patients due to reduced clearance and comedication with CYP3A4 or CYP2C9 inhibitors. Elevated Ruxolitinib trough concentrations might be a surrogate for toxicity.
Using data from the German Hepatitis C-Registry (Deutsche Hepatitis C-Register, DHC-R), we report the real-world safety and effectiveness of glecaprevir/pibrentasvir (GLE/PIB) treatment and its impact on patient-reported outcomes (PROs) in underserved populations who are not typically included in clinical trials, yet who will be crucial for achieving hepatitis C virus (HCV) elimination. The DHC-R is an ongoing, non-interventional, multicenter, prospective, observational cohort study on patients treated for chronic HCV infection in Germany. The data cutoff was 17 January 2021. The primary effectiveness endpoint was sustained virologic response at post-treatment Week 12 (SVR12). Safety outcomes were assessed in all patients receiving GLE/PIB. PROs were assessed using the SF-36 survey. Of 2354 patients, 1964 had valid SVR12 data (intention-to-treat analysis). Of these, 1905 (97.0%) achieved SVR12 with rates similar across the comorbidities analyzed, except for people who actively use drugs (PWUD (active)) (86.4%). Excluding those who discontinued treatment and did not achieve SVR12, or were reinfected with HCV, the rate was 99.3%, with similar results regardless of comorbidity. PWUD (active) and those with psychiatric disorders had the most meaningful improvements in PROs. Adverse events (AEs) occurred in 631/2354 patients (26.8%), and serious AEs in 44 patients (1.9%). GLE/PIB was highly effective and well tolerated in this real-world study of patient groups key to HCV elimination.